Endocrine Abstracts

JOINT2556

Background: Cardiovascular complications are a major cause of premature mortality in patients with acromegaly. Copeptin (CPP) is closely associated with plasma osmolality and is influenced by non-osmotic stimuli that play a role in the development of cardiovascular disease. Mid-regional proadrenomedullin (MR-proADM), primarily produced in the adrenal medulla, vascular endothelial cells, and the heart, has known vasodilatory effects. This study aimed to evaluate two cardiovascular biomarkers (CPP and MR-proADM) in patients with acromegaly concerning disease activity and to compare the results with those of a control group.

Methods: The study analyzed CPP and MR-proADM levels, along with hormonal and biochemical parameters, and the prevalence of cardiovascular and metabolic diseases in 53 patients with acromegaly and 26 controls.

Results: No significant differences were found in CPP or MR-proADM levels between the two groups. However, a positive correlation was observed between growth hormone (GH) and CPP levels, while a negative correlation was noted between fasting glucose and CPP levels among acromegaly patients. Additionally, there was a positive correlation between low-density lipoprotein (LDL) and MR-proADM levels, as well as between high-density lipoprotein (HDL) and MR-proADM levels in the study group. Atherogenic dyslipidemia was significantly more prevalent in patients with active acromegaly and pituitary macroadenomas compared to the control group. Acromegaly patients also exhibited significantly higher fasting glucose and insulin levels than controls.

Conclusions: Neither CPP nor MR-proADM serves as significant diagnostic or monitoring biomarkers for cardiovascular or metabolic complications in patients with acromegaly.